These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 27624520)
1. An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain. Ronsisvalle S; Aricò G; Panarello F; Spadaro A; Pasquinucci L; Pappalardo MS; Parenti C; Ronsisvalle N Bioorg Med Chem; 2016 Nov; 24(21):5280-5290. PubMed ID: 27624520 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of N-substituent structural variations in opioid receptor profile of LP1. Pasquinucci L; Turnaturi R; Aricò G; Parenti C; Pallaki P; Georgoussi Z; Ronsisvalle S Bioorg Med Chem; 2016 Jun; 24(12):2832-42. PubMed ID: 27234885 [TBL] [Abstract][Full Text] [Related]
3. Development of novel LP1-based analogues with enhanced delta opioid receptor profile. Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists. Turnaturi R; Parenti C; Prezzavento O; Marrazzo A; Pallaki P; Georgoussi Z; Amata E; Pasquinucci L Molecules; 2018 Mar; 23(3):. PubMed ID: 29547588 [TBL] [Abstract][Full Text] [Related]
5. The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment. Pasquinucci L; Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Ronsisvalle G Life Sci; 2012 Jan; 90(1-2):66-70. PubMed ID: 22100511 [TBL] [Abstract][Full Text] [Related]
6. (2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist. Pasquinucci L; Turnaturi R; Calò G; Pappalardo F; Ferrari F; Russo G; Arena E; Montenegro L; Chiechio S; Prezzavento O; Parenti C Eur J Med Chem; 2019 Apr; 168():189-198. PubMed ID: 30822708 [TBL] [Abstract][Full Text] [Related]
7. Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L Life Sci; 2012 Jun; 90(25-26):957-61. PubMed ID: 22580287 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of N-substitution in 6,7-benzomorphan compounds. Pasquinucci L; Prezzavento O; Marrazzo A; Amata E; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Parenti C; Aricò G; Ronsisvalle G Bioorg Med Chem; 2010 Jul; 18(14):4975-82. PubMed ID: 20599386 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and Structure-Activity Relationships of (-)- Pasquinucci L; Parenti C; Amata E; Georgoussi Z; Pallaki P; Camarda V; Calò G; Arena E; Montenegro L; Turnaturi R Pharmaceuticals (Basel); 2018 May; 11(2):. PubMed ID: 29734749 [TBL] [Abstract][Full Text] [Related]
10. The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures. Parenti C; Turnaturi R; Aricò G; Gramowski-Voss A; Schroeder OH; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L Neuropharmacology; 2013 Aug; 71():70-82. PubMed ID: 23541722 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands. Costanzo G; Patamia V; Turnaturi R; Parenti C; Zagni C; Lombino J; Amata E; Marrazzo A; Pasquinucci L; Rescifina A Chem Biol Drug Des; 2023 Jun; 101(6):1382-1392. PubMed ID: 36813756 [TBL] [Abstract][Full Text] [Related]
12. New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands. Pasquinucci L; Iadanza M; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Parenti C; De Luca L; Ronsisvalle G Pharmazie; 2007 Nov; 62(11):813-24. PubMed ID: 18065096 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975 [TBL] [Abstract][Full Text] [Related]
14. Exploiting the Power of Stereochemistry in Drug Action: 3-[(2 Turnaturi R; Pasquinucci L; Chiechio S; Grasso M; Marrazzo A; Amata E; Dichiara M; Prezzavento O; Parenti C ACS Chem Neurosci; 2020 Apr; 11(7):999-1005. PubMed ID: 32186844 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties and biochemical mechanisms of μ-opioid receptor ligands might be due to different binding poses: MD studies. Ronsisvalle S; Panarello F; Spadaro A; Franchini S; Pappalardo M; Guccione S; Basile L Future Med Chem; 2020 Nov; 12(22):2001-2018. PubMed ID: 32972243 [No Abstract] [Full Text] [Related]
16. Label-free cell phenotypic study of opioid receptors and discovery of novel mu opioid ligands from natural products. Hou T; Xu F; Peng X; Zhou H; Zhang X; Qiu M; Wang J; Liu Y; Liang X J Ethnopharmacol; 2021 Apr; 270():113872. PubMed ID: 33485984 [TBL] [Abstract][Full Text] [Related]